Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials

Table 6: Fasting Plasma Glucose (Expressed as mg/dL) During the GUIDE Study in Patients with Baseline Levels Above the Upper Normal Limit (UNL; 110 mg/dL)

Evaluation Time	Study Treatment (n=tot pts; n=pts>UNL)	Values at Each Time Point	Delta at Each Time Point
Baseline	Placebo (n=15; n=15)	124 (12)	-
Baseline	CGS (n=12; n=12)	129 (17)	-
Month 3	Placebo (n=14; n=12)	125 (14)	2 (9)
Month 3	CGS (n=10; n=7)	122 (22)	-4 (10)
Month 6	Placebo (n=14; n=12)	125 (15)	1 (10)
Month 6	CGS (n=10; n=7)	120 (20)	-6 (8)

Values are expressed as mean (SD); p=not significant in all comparisons.n=tot pts: number of patients with an abnormal glucose value at baseline and, of these, number of patients whose glucose levels were available after 3 and 6 months.n=pts>UNL: number of patients with a glucose level above UNL at each time point.